Message from the Guest Editor

Dear Colleagues,

The idea of targeting angiogenesis to inhibit tumor growth was proposed more than three decades ago by Judah Folkman, and since then several approaches to block or disrupt tumor angiogenesis have been explored.

Antiangiogenesis remains a dynamic and evolving field in oncology. New therapeutic targets continue to emerge followed by the rapid development of new therapeutic agents to be investigated in clinical trials.

Until now, the success of antiangiogenic compounds in the clinic is rather limited when given as monotherapies. This is in contrast with many preclinical results which revealed a much higher efficacy of these agents in animal models.

Prof. Dr. Domenico Ribatti
Guest Editor